Unknown PHASE2 INTERVENTIONAL 2-arm NCT02353988

AR-inhibitor Bicalutamide in Treating Patients With TNBC (Arbre)

Bicalutamide in Treating Patients With AR-positive Metastatic Triple Negative Breast Cancer

Sponsor: Jiangsu Province Hospital of Traditional Chinese Medicine

Interventions Bicalutamide Physician's Choice

Updated 6 times since 2017 Last updated: Feb 2, 2015 Started: Jan 31, 2015 Primary completion: Jan 31, 2017 Completion: May 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02353988, this PHASE2 trial focuses on Breast Neoplasms and remains ongoing. Sponsored by Jiangsu Province Hospital of Traditional Chinese Medicine, it has been updated 6 times since 2015, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jun 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Not Yet Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Jun 2017 [monthly]

Not Yet Recruiting PHASE2

First recorded

Jan 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Province Hospital of Traditional Chinese Medicine
Jinling Hospital, China
Nanning Second People's Hospital
The First People's Hospital of Lianyungang
The Second Hospital of Nanjing Medical University
Wenzhou Medical University
Wuxi People's Hospital

Data source: Jinling Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.